Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11847MR)

This product GTTS-WQ11847MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11847MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11469MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ6616MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ7008MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ6666MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ15559MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ13613MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ8285MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ4433MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW